ERYTECH announces positive safety review for eryaspase in its Phase 2 study in pancreatic cancer

ERYTECH announces a positive DSMB safety review following the treatment of the first twenty-four patients with eryaspase in its Phase 2 study in pancreatic cancer.

Menu